Encompass More Asset Management Purchases New Holdings in AstraZeneca PLC (NASDAQ:AZN)

Encompass More Asset Management acquired a new position in AstraZeneca PLC (NASDAQ:AZN) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 4,797 shares of the company’s stock, valued at approximately $314,000.

Several other institutional investors also recently modified their holdings of AZN. Point72 Hong Kong Ltd acquired a new position in AstraZeneca in the second quarter worth about $518,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of AstraZeneca by 122.4% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,728 shares of the company’s stock worth $135,000 after buying an additional 951 shares in the last quarter. AXA S.A. lifted its position in shares of AstraZeneca by 1,039.6% during the 2nd quarter. AXA S.A. now owns 400,242 shares of the company’s stock worth $31,215,000 after buying an additional 365,121 shares during the period. AQR Capital Management LLC boosted its stake in AstraZeneca by 112.4% in the 2nd quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock valued at $1,067,000 after buying an additional 7,241 shares in the last quarter. Finally, Daymark Wealth Partners LLC grew its position in AstraZeneca by 6.8% in the second quarter. Daymark Wealth Partners LLC now owns 5,849 shares of the company’s stock valued at $456,000 after acquiring an additional 372 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AZN shares. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $69.06 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a market cap of $214.16 billion, a price-to-earnings ratio of 33.04, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The stock’s 50-day moving average is $66.33 and its 200-day moving average is $74.24.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.87 earnings per share. Equities analysts predict that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.